Roundtable on Black in cancer research and oncology - presented by Dr. Brandon Blue MD and Dr. Kilan Ashad-Bishop and Drs. Onyinye and Folu Balogun and Runcie C.W. Chidebe Dip., BSc., MSc., and Kathryn Mcginnis and Dr Paraskevi Mallini and Dr. Lisa Hoffmann-Haas

Roundtable on Black in cancer research and oncology

Brandon Blue, Kilan Ashad-Bishop, Onyinye and Folu Balogun and Runcie C.W. Chidebe

Dr. Brandon Blue MDDr. Kilan Ashad-BishopDrs. Onyinye and Folu BalogunRuncie C.W. Chidebe Dip., BSc., MSc.,
Slide at 02:08
Background Dr. Brandon Blue Timeline Contributions of Jurkat T cells to characterizing the T-cell receptor signalling pathway Characterization of ZAP70 Discovery that TOR Observation that TCR Identification identification ligation triggers stimulation triggers identification of PLC-y1 Characterization of of ZAP70 Characterization of the Jurkat intracellular Ca protein tyrosine as a TCR-linked signaling LCK expression defect deficient of CARMA1 in MHC Class cell line mobilization phosphoryation enzyme in J.CAM1 cells Jurkat cells Jurkat cells 1980 1984 1987 1990 1991 1992 1998 2002 T cell Discovery that Use of TCR/CD3- Generation of Reports that Identification of ITAMs as Characterization of LAT- CHANGE Jurkat cells specific antibodies J.CaM-3 mutants protein tyrosine signal-transducing motifs deficient Jurkat cells release L-2 as stimuli for L-2 phosphorylation in the CD3 cytoplasmic when stimulated production by is required for domain with PHA Jurkat cells TCR signaling IL-2, interleukin-2: ITAM, immunoreceptor tyrosine-based activation motif; LAT, linker for activation of T cells: PHA, phytohaemagglutinin; PLC-y1. phospholipase C-y1: TCR, T-cell receptor; IP's ZAP70, t-chain-associated protein of 70kD. Intraculular Ca?- MAPK L2 gene expression Cytoskeistal Call-cycle entry effector functions management Figure 2 Proximal signalling complexes and downstream responses induced by T-cell receptor (TCR) ligation. Amodel outlining our current knowledge of TCR and inker for activation of cells(LAT)
1
References
  • 1.
    R. T. Abraham and A. Weiss (2004) Jurkat T cells and development of the T-cell receptor signalling paradigm. Nature Reviews Immunology
Share slide
Summary (AI generated)

One of the specialties we focus on is stem cell transplants, along with a newer therapy called car T cell or chimeric antigen t-cell receptor therapy. This concept has been around for decades, with the idea of utilizing the immune system to combat cancer. Our immune system plays a vital role in fighting off various illnesses such as bacteria, COVID, and pneumonia. However, through extensive research, we have discovered a method to utilize the T cells' potential to fight against cancer instead.